Remission induced by Campath-1H for thymoma-associated agranulocytosis.
Thymoma-associated agranulocytosis is a rare but almost universally fatal condition. Reports to date have described several immunosuppressive therapies including steroids, cyclophosphamide and vincristine as adjuvants to thymectomy, in an effort to improve neutropenia. We report the response to the monoclonal antibody Campath-1H of a patient with a thymoma and associated agranulocytosis with complete absence of bone marrow granulocyte precursors, which had failed to respond to thymectomy. Treatment with Campath-1H resulted in complete responses of promising durability sustained with the addition of cyclosporin and mycophenolate mofetil as maintenance therapy.
Alvares
C L
CL
Department of Haematology, St George's Hospital Medical School, Cranmer Terrace, London, SW17 ORE, UK.
Svasti-Salee
D
D
Rowley
M
M
Gordon-Smith
E C
EC
Marsh
J C W
JC
D000380:Agranulocytosis / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013934:Thymectomy; D013945:Thymoma / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000628:therapy; D013953:Thymus Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab